Literature DB >> 24789253

Brain metastasis from ovarian cancer: a systematic review.

Shabnam Pakneshan1, Damoun Safarpour, Fattaneh Tavassoli, Bahman Jabbari.   

Abstract

To review the existing literature on brain metastasis (BM) from ovarian cancer and to assess the frequency, anatomical, clinical and paraclinical information and factors associated with prognosis. Ovarian cancer is a rare cause of brain metastasis with a recently reported increasing prevalence. Progressive neurologic disability and poor prognosis is common. A comprehensive review on this subject has not been published previously. This systematic literature search used the Pubmed and Yale library. A total of 66 publications were found, 57 of which were used representing 591 patients with BM from ovarian cancer. The median age of the patients was 54.3 years (range 20-81). A majority of patients (57.3 %) had multiple brain lesions. The location of the lesion was cerebellar (30 %), frontal (20 %), parietal (18 %) and occipital (11 %). Extracranial metastasis was present in 49.8 % of cases involving liver (20.7 %), lung (20.4 %), lymph nodes (12.6 %), bones (6.6 %) and pelvic organs (4.3 %). The most common symptoms were weakness (16 %), seizures (11 %), altered mentality (11 %) visual disturbances (9 %) and dizziness (8 %). The interval from diagnosis of breast cancer to BM ranged from 0 to 133 months (median 24 months) and median survival was 8.2 months. Local radiation, surgical resection, stereotactic radiosurgery and medical therapy were used. Factors that significantly increased the survival were younger age at the time of ovarian cancer diagnosis and brain metastasis diagnosis, lower grade of the primary tumor, higher KPS score and multimodality treatment for the brain metastases. Ovarian cancer is a rare cause of brain metastasis. Development of brain metastasis among older patients and lower KPS score correlate with less favorable prognosis. The more prolonged survival after using multimodality treatment for brain metastasis is important due to potential impact on management of brain metastasis in future.

Entities:  

Mesh:

Year:  2014        PMID: 24789253     DOI: 10.1007/s11060-014-1447-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

1.  Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.

Authors:  Koji Matsuo; Michele L Eno; Edward H Ahn; Mian M K Shahzad; Dwight D Im; Neil B Rosenshein; Anil K Sood
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

2.  Prolonged relapse-free survival in two patients with an isolated brain metastasis from epithelial ovarian carcinoma.

Authors:  Bok A Choo; Nawaz Walji; David Spooner; Peter Barber; Indrajit N Fernando
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

3.  Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study.

Authors:  J Sehouli; K Pietzner; P Harter; K Münstedt; S Mahner; A Hasenburg; O Camara; P Wimberger; D Boehmer; K J Buehling; R Richter; K El Khalfaoui; G Oskay-Ozcelik
Journal:  Ann Oncol       Date:  2010-05-03       Impact factor: 32.976

4.  Brain metastases from epithelial ovarian carcinoma.

Authors:  M.-C. Kaminsky-Forrett; B. Weber; T. Conroy; D. Spaëth
Journal:  Int J Gynecol Cancer       Date:  2000-09       Impact factor: 3.437

5.  Central nervous system metastases in epithelial ovarian carcinoma.

Authors:  D M Larson; L J Copeland; R P Moser; J M Malone; D M Gershenson; J T Wharton
Journal:  Obstet Gynecol       Date:  1986-12       Impact factor: 7.661

Review 6.  Intramedullary metastasis in breast cancer--a comprehensive literature review.

Authors:  Rezvan Rostami; Damoun Safarpour; Fattaneh A Tavassoli; Bahman Jabbari
Journal:  J Neurol Sci       Date:  2013-06-15       Impact factor: 3.181

7.  Evaluation of prognostic factors and treatment modalities in ovarian cancer patients with brain metastases.

Authors:  Noel Anupol; Sharad Ghamande; Kunle Odunsi; Deborah Driscoll; Shashikant Lele
Journal:  Gynecol Oncol       Date:  2002-06       Impact factor: 5.482

Review 8.  Brain metastases.

Authors:  M G Ewend; L A Carey; D E Morris; R D Harvey; T A Hensing
Journal:  Curr Treat Options Oncol       Date:  2001-12

9.  Distant metastases in ovarian carcinoma.

Authors:  G Cormio; C Rossi; A Cazzolla; L Resta; G Loverro; P Greco; L Selvaggi
Journal:  Int J Gynecol Cancer       Date:  2003 Mar-Apr       Impact factor: 3.437

10.  Quality of life in brain metastases radiation trials: a literature review.

Authors:  J Wong; A Hird; A Kirou-Mauro; J Napolskikh; E Chow
Journal:  Curr Oncol       Date:  2008-10       Impact factor: 3.677

View more
  31 in total

1.  βIII-Tubulin Regulates Breast Cancer Metastases to the Brain.

Authors:  Deepak Kanojia; Ramin A Morshed; Lingjiao Zhang; Jason M Miska; Jian Qiao; Julius W Kim; Peter Pytel; Irina V Balyasnikova; Maciej S Lesniak; Atique U Ahmed
Journal:  Mol Cancer Ther       Date:  2015-02-27       Impact factor: 6.261

Review 2.  Brain metastasis in breast cancer: a comprehensive literature review.

Authors:  Rezvan Rostami; Shivam Mittal; Pooya Rostami; Fattaneh Tavassoli; Bahman Jabbari
Journal:  J Neurooncol       Date:  2016-02-24       Impact factor: 4.130

3.  Tumor immune microenvironment in brain metastases from gynecologic malignancies.

Authors:  Corey M Gill; Megan R D'Andrea; Shannon Tomita; Jessa Suhner; Melissa Umphlett; Konstantin Zakashansky; Stephanie V Blank; Nadejda Tsankova; Raj K Shrivastava; Mary Fowkes; Valentin Kolev
Journal:  Cancer Immunol Immunother       Date:  2021-03-13       Impact factor: 6.968

Review 4.  Therapeutic Options for Brain Metastases in Gynecologic Cancers.

Authors:  Adeola Akapo; Kseniya Anishchenko; Carolyn Lefkowits; Ashley L Greenwood
Journal:  Curr Treat Options Oncol       Date:  2022-10-18

5.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

6.  Platinum sensitivity and CD133 expression as risk and prognostic predictors of central nervous system metastases in patients with epithelial ovarian cancer.

Authors:  Bo-Lin Liu; Shu-Juan Liu; Andrius Baskys; Hong Cheng; Ying Han; Chao Xie; Hui Song; Jia Li; Xiao-Yan Xin
Journal:  BMC Cancer       Date:  2014-11-17       Impact factor: 4.430

7.  Late isolated central nervous system relapse from ovarian serous adenocarcinoma: a case report and literature review.

Authors:  Tiago Biachi de Castria; Sylvia Regina Quintanilha Rodrigues; Maria Del Pilar Estevez Diz
Journal:  Case Rep Obstet Gynecol       Date:  2014-11-18

8.  Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease.

Authors:  Madeleine Bangham; Robert Goldstein; Henry Walton; Jonathan A Ledermann
Journal:  Gynecol Oncol Rep       Date:  2016-10-19

9.  Radiosurgery for brain metastases from ovarian cancer: an analysis of 25 years' experience with Gamma Knife treatment.

Authors:  Rosa Maria Leon-Salas Ordoñez; Beatriz E Amendola; Paul F Martinez; Aizik Wolf; Sammie R Coy; Marco Amendola
Journal:  Rep Pract Oncol Radiother       Date:  2019-10-30

10.  Cerebellar preference of luminal A and B type and basal ganglial preference of HER2-positive type breast cancer-derived brain metastases.

Authors:  Nobuyuki Izutsu; Manabu Kinoshita; Tomohiko Ozaki; Mio Sakai; Katsuyuki Nakanishi; Takahiro Nakayama; Yasuhiro Tamaki; Haruhiko Kishima
Journal:  Mol Clin Oncol       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.